googlefd16b42746daa692.html

IFIs and Ibrutinib

ibrutinib IFI.png

While novel immunotherapies such as Immune checkpoint inhibitors and tyrosine kinase inhibitors have revolutionised cancer therapy the effect on the immunocompromised host is unclear. This recent review investigates the link between invasive fungal infection risk and new and emerging immunotherapies.

googlefd16b42746daa692.html